On Jan. 4, 2017, Abbott announced it had completed the acquisition of St. Jude Medical, establishing the company as a leader in the medical device arena in a cash-and-stock deal worth $25 billion.

St. Jude Medical’s strong positions in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain complement Abbott’s leading positions in coronary interventions and mitral valve disease.